Pilgrim's Pride Corporation - 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended April 1, 2000 (26 weeks) and the six-month period ended April 1, 2000, compared to the prior year periods (27 weeks). Pilgrim's Pride Corporation is an integrated poultry producer and processor. The company operates primarily in the United States and Mexico, focusing on chicken production, prepared food products, and poultry by-products.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Apr 1, 2000 | 6 Months Ended Apr 1, 2000 |
|---|---|---|
| Net Sales | $373,260 | $728,085 |
| Cost of Sales | $339,231 | $648,580 |
| Gross Profit | $34,029 | $79,505 |
| Operating Income | $13,282 | $38,504 |
| Net Income | $9,023 | $23,881 |
| Net Income Per Share | $0.22 | $0.58 |
| Cash from Operations (6 mo) | $43,408 | |
| Capital Expenditures (6 mo) | ($35,368) | |
| Total Debt (Current + Long-Term) | $180,391 | |
| Working Capital | $139,465 |
Liquidity: Cash and cash equivalents stood at $10.47 million as of April 1, 2000. The company maintains $70 million in revolving credit facilities and $200 million in secured revolving/term borrowing facilities, with significant availability remaining.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13.2% ($43.4 million) for the quarter and 9.3% ($62.1 million) for the six months compared to the prior year. Growth was driven by higher volumes in both U.S. and Mexico operations and increased revenue per dressed pound in Mexico.
- Margin Compression: Gross profit margins declined significantly. For the quarter, gross profit fell 26.4% to $34.0 million (9.1% of sales vs. 14.0% prior year). For the six months, gross profit fell 11.8% to $79.5 million (10.9% of sales vs. 13.5% prior year).
- Profitability Decline: Operating income decreased 47.5% for the quarter and 25.2% for the six months. Net income dropped 38.1% for the quarter and 21.7% for the six months.
- Balance Sheet: Inventories increased 10.6% to $185.8 million, primarily due to higher prepared food inventories. Accounts receivable decreased 30.7% to $58.4 million, largely due to the sale of $39.8 million in receivables under an asset sale agreement.
Outlook, Risks, and Unusual Items
Management Commentary: Management attributes the decline in margins to lower U.S. poultry market prices, higher feed costs, and increased production volumes. The company is shifting strategy toward prepared food products to mitigate commodity price volatility.
Unusual Items:
- AmeriServe Write-off: A $5.8 million write-off of accounts receivable was recorded due to the bankruptcy of AmeriServe, a significant distributor.
- Weather Impact: Losses were realized from an ice storm in late January 2000 affecting U.S. operations.
- Stock Repurchase: On March 31, 2000, the Board authorized a $25 million stock repurchase program. No shares had been repurchased as of April 19, 2000.
Risks and Contingencies:
- Legal Proceedings: The company is a plaintiff in a vitamin antitrust class action lawsuit (potential recovery of 18-20% of purchases from 1990-1998, approx. $19.0 million). It is also a defendant in a Fair Labor Standards Act class action regarding unpaid wages (approx. 1,700 plaintiffs), with a trial expected in August 2000.
- Regulatory Audit: The U.S. Department of Labor initiated a nationwide audit of wage and hour practices in the poultry industry, including one of the company's plants.
- Market Risk: Earnings are cyclical and sensitive to feed ingredient costs (approx. 30.9% of cost of goods sold) and chicken commodity prices.
Investor Verification Checklist
- Verify the impact of the $5.8 million AmeriServe receivable write-off on future bad debt provisions.
- Monitor the outcome of the Fair Labor Standards Act class action lawsuit and the DOL audit regarding wage and hour practices.
- Assess the sustainability of the shift to prepared food products as a hedge against feed cost volatility.
- Review the status of the $25 million stock repurchase program and its execution timeline.
- Track the resolution of the vitamin antitrust settlement and the timing of expected cash recoveries.